Tag Archives: Survival

Jan 28

Molecular test more accurate in predicting lung cancer survival

Posted on by


FREE Samples and Coupons for Brand Name Products!

Molecular test more accurate in predicting lung cancer survival
Washington, Jan 27 (ANI): An available molecular test can predict the likelihood of death from early-stage lung cancer more accurately than conventional methods, according to a team of scientists. The international team, led by scientists at the …
Read more on TruthDive

New breath technology to detect lung cancer
This infrared-based technology developed by Picomole Instruments Inc. may be able to detect lung cancer.This infrared-based technology developed by Picomole Instruments Inc. may be able to detect lung cancer. (John Cormier/Picomole) The Atlantic Cancer …
Read more on CBC.ca

Gene Test Predicts Mortality Risk After Lung Cancer Surgery
By Kristina Fiore, Staff Writer, MedPage Today This study found that a new assay looking for 14 genetic signatures may help predict which patients with early-stage lung cancer are more likely to die even after their tumors have been removed.
Read more on MedPage Today


Discount Canadian Drugs

Dec 10

Afatinib (BIBW 2992*) Triples Progression Free Survival in Lung Cancer Patients

Posted on by


FREE Samples and Coupons for Brand Name Products!

Boehringer Ingelheim announced promising results from two clinical trials of its investigational cancer compound afatinib (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy. Results from the LUX-Lung 1 trial suggest that afatinib (BIBW 2992) is highly active in late-stage patients with NSCLC1, while in the LUX-Lung 2 phase II trial afatinib demonstrated encouraging activity in advanced NSCLC patients that have a mutated EGF Receptor.

Afatinib, which is taken as a tablet, is a next generation inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) tyrosine kinase (TK) and unlike first generation TKIs irreversibly binds to EGFR/HER2. The compound is under development in several solid tumour types.

The LUX-Lung 1 trial (phase II b/III) compared afatinib to placebo in over 580 patients with advanced NSCLC whose disease has progressed after receiving chemotherapy and a first-generation EGFR Tyrosine Kinase Inhibitor (gefitinib or erlotinib)  results showed1:

* Even though the LUX-Lung 1 trial did not meet the primary endpoint of prolonging overall survival (OS), afatinib significantly extended the time before the tumour progressed; specifically it led to a three-fold extension of progression-free survival (PFS, key secondary endpoint) from 1.1 months to 3.3 months over placebo.
* The PFS benefit was apparent as a robust effect across all patient subgroups and has been confirmed by independent review.
* There was a significantly higher rate of tumour control or shrinkage in those patients who took afatinib (disease control rate: 58%) versus those taking placebo (disease control rate: 19%); also independently verified.
* Afatinib significantly improved the lung-cancer related symptoms cough, dyspnea (shortness of breath) and pain, and delayed the time to deterioration of cough, individual dyspnea items and chest pain significantly.
* There were no new or unexpected safety findings; the main side effects were diarrhea and rash.

The results of LUX-Lung 1 in a special patient population whose cancers probably have a high incidence of EGFR mutations have substantially contributed to better understanding of the biology of these tumours.

Conclusions from the trial will be relevant for the design of further clinical studies, which will evaluate further patient populations and their mutation status.

Lung cancer is the most common and most deadly form of cancer in the world, accounting for 1.6 million new cancer cases annually and 1.4 million deaths2 from lung cancer. Lung cancer remains an area of high unmet need, especially in its advanced stages where it is particularly aggressive and patients have limited treatment options. No approved therapy is currently available for patients with advanced lung cancer who have failed chemotherapy and progressed after treatments with EGFR TKI.

In clinical practice, it is of high relevance to patients to have improvement in key lung cancer related symptoms such as cough, shortness of breath and pain? commented Dr Vera Hirsh, investigator of the trial, and Chair of the Lung Cancer Committee, McGill University, Canada. Furthermore, the time to deterioration, meaning the time before the symptoms get worse, was significantly extended for some of these symptoms in the LUX Lung 1 study.

This is the first time that a compound has demonstrated in a controlled study, a clinically meaningful improvement in PFS in patients with NSCLC who have progressed on first generation EGFR TKIs.

Encouraging results were also presented for LUX-Lung 2, a phase II trial studying patients with advanced NSCLC who harbour EGFR mutations. This result shows that the use of afatinib led to a high rate of tumour size reduction (overall response rate of 61%) and a long delay in the progression of cancer by over 1 year (PFS of 14 months)3. These results help to underline afatinib?s potential benefit as a first or second line treatment in patients with EGFR mutations. Two phase III trials, LUX-Lung 3 and LUX-Lung 6 are currently underway to further evaluate afatinib as a first-line treatment in this patient group.

Afatinibs clinical trial programme: LUX Trial Programme

The LUX-trial programme is a comprehensive and robust programme that comprises more than ten trials conducted across the globe, investigating afatinib in a variety of different solid tumour types, including NSCLC, breast and head and neck cancer.

LUX-Lung 1 is a phase III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with chemotherapy and first generation EGFR-TKIs, erlotinib or gefitinib.

LUX-Lung 2 is a phase II trial evaluating afatinib in NSCLC patients with EGFR mutations, either chemotherapy naïve or after one line of chemotherapy.

In two further ongoing global phase III trials, LUX-Lung 3 and LUX-Lung 6, the efficacy and safety profile of afatinib is compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations in different geographical regions.

Another trial, LUX-Lung 5, is a global phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomised phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may further benefit from afatinib beyond progression when given in combination with chemotherapy.

Further indications

Additionally, Boehringer Ingelheim has recently commenced a phase III clinical trial evaluating afatinib in advanced breast cancer (LUX-Breast 1).

Afatinib is also being investigated in head and neck cancer, glioblastoma and colorectal cancer.

Afatinib & BIBF 1120*: the two front-runner molecules within Boehringer Ingelheim?s investigational oncology portfolio

Apart from afatinib, Boehringer Ingelheim?s late stage oncology portfolio includes BIBF 1120, also in phase III development for the treatment of patients in two different indications, advanced NSCLC and ovarian cancer.

BIBF 1120 is a triple angiokinase inhibitor that acts on three growth factors simultaneously: vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR) all crucially involved in the formation of blood vessels, which supply tumours with nutrients and oxygen needed for the cancer to grow.

About lung cancer

Lung cancer is the world’s most common cancer and kills more people than any other cancer.In 2008, approximately 1.6 million new cases of lung cancer were diagnosed worldwide, with 1.4 million people dying from the disease.2

About breast cancer

There are more than one and a half million cases of breast cancer diagnosed each year4. It is the leading cause of cancer deaths in women worldwide, resulting in more than 500,000 deaths per year. Breast cancer accounts for around a third of all cancers diagnosed in women, making it the most commonly diagnosed tumour type in females5.

About head and neck cancer

Head and neck cancer can occur in over 30 different places in any of the tissues or organs in the head and neck6 and is the sixth most frequently occurring cancer worldwide7. Most head and neck cancers are squamous cell carcinomas8 over 90% of which express EGFR9 which is critical for tumour growth.10

About ovarian cancer

Each year approximately 204,000 new cases of ovarian cancer are diagnosed in women worldwide, with an estimated 125,000 dying of the disease each year11. One of the greatest challenges in the management of ovarian cancer is that the majority of cases are not found at an early stage11 (when definitive cure is possible by surgery) since the tumour usually causes only non-specific symptoms, commonly attributed to non-serious causes.

Boehringer Ingelheim announced promising results from two clinical trials of its investigational cancer compound

afatinib (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

Results from the LUX-Lung 1 trial suggest that afatinib (BIBW 2992) is highly active in late-stage patients with

NSCLC1, while in the LUX-Lung 2 phase II trial afatinib demonstrated encouraging activity in advanced NSCLC patients

that have a mutated EGF Receptor.

Afatinib, which is taken as a tablet, is a next generation inhibitor of the epidermal growth factor receptor (EGFR)

and human epidermal receptor 2 (HER2) tyrosine kinase (TK) and unlike first generation TKIs irreversibly binds to

EGFR/HER2. The compound is under development in several solid tumour types.

The LUX-Lung 1 trial (phase II b/III) compared afatinib to placebo in over 580 patients with advanced NSCLC whose

disease has progressed after receiving chemotherapy and a first-generation EGFR Tyrosine Kinase Inhibitor (gefitinib

or erlotinib)  results showed1:

* Even though the LUX-Lung 1 trial did not meet the primary endpoint of prolonging overall survival (OS),

afatinib significantly extended the time before the tumour progressed; specifically it led to a three-fold extension

of progression-free survival (PFS, key secondary endpoint) from 1.1 months to 3.3 months over placebo.
* The PFS benefit was apparent as a robust effect across all patient subgroups and has been confirmed by

independent review.
* There was a significantly higher rate of tumour control or shrinkage in those patients who took afatinib

(disease control rate: 58%) versus those taking placebo (disease control rate: 19%); also independently verified.
* Afatinib significantly improved the lung-cancer related symptoms cough, dyspnea (shortness of breath) and pain,

and delayed the time to deterioration of cough, individual dyspnea items and chest pain significantly.
* There were no new or unexpected safety findings; the main side effects were diarrhea and rash.

The results of LUX-Lung 1 in a special patient population whose cancers probably have a high incidence of EGFR

mutations have substantially contributed to better understanding of the biology of these tumours. Conclusions from

the trial will be relevant for the design of further clinical studies, which will evaluate further patient

populations and their mutation status.

Lung cancer is the most common and most deadly form of cancer in the world, accounting for 1.6 million new cancer

cases annually and 1.4 million deaths2 from lung cancer. Lung cancer remains an area of high unmet need, especially

in its advanced stages where it is particularly aggressive and patients have limited treatment options. No approved

therapy is currently available for patients with advanced lung cancer who have failed chemotherapy and progressed

after treatments with EGFR TKI.

In clinical practice, it is of high relevance to patients to have improvement in key lung cancer related symptoms

such as cough, shortness of breath and pain? commented Dr Vera Hirsh, investigator of the trial, and Chair of the

Lung Cancer Committee, McGill University, Canada. Furthermore, the time to deterioration, meaning the time before the

symptoms get worse, was significantly extended for some of these symptoms in the LUX Lung 1 study.

This is the first time that a compound has demonstrated in a controlled study, a clinically meaningful improvement in

PFS in patients with NSCLC who have progressed on first generation EGFR TKIs.

Encouraging results were also presented for LUX-Lung 2, a phase II trial studying patients with advanced NSCLC who

harbour EGFR mutations. This result shows that the use of afatinib led to a high rate of tumour size reduction

(overall response rate of 61%) and a long delay in the progression of cancer by over 1 year (PFS of 14 months)3.

These results help to underline afatinib?s potential benefit as a first or second line treatment in patients with

EGFR mutations. Two phase III trials, LUX-Lung 3 and LUX-Lung 6 are currently underway to further evaluate afatinib

as a first-line treatment in this patient group.

Afatinibs clinical trial programme: LUX Trial Programme

The LUX-trial programme is a comprehensive and robust programme that comprises more than ten trials conducted across

the globe, investigating afatinib in a variety of different solid tumour types, including NSCLC, breast and head and

neck cancer.

LUX-Lung 1 is a phase III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in

NSCLC patients who were previously treated with chemotherapy and first generation EGFR-TKIs, erlotinib or gefitinib.

LUX-Lung 2 is a phase II trial evaluating afatinib in NSCLC patients with EGFR mutations, either chemotherapy naïve

or after one line of chemotherapy.

In two further ongoing global phase III trials, LUX-Lung 3 and LUX-Lung 6, the efficacy and safety profile of

afatinib is compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations in

different geographical regions.

Another trial, LUX-Lung 5, is a global phase III trial in patients previously treated with erlotinib or gefitinib.

This is the first randomised phase III trial investigating whether patients who initially benefit from treatment with

afatinib alone may further benefit from afatinib beyond progression when given in combination with chemotherapy.

Further indications

Additionally, Boehringer Ingelheim has recently commenced a phase III clinical trial evaluating afatinib in advanced

breast cancer (LUX-Breast 1).

Afatinib is also being investigated in head and neck cancer, glioblastoma and colorectal cancer.

Afatinib & BIBF 1120*: the two front-runner molecules within Boehringer Ingelheim?s investigational oncology

portfolio

Apart from afatinib, Boehringer Ingelheim?s late stage oncology portfolio includes BIBF 1120, also in phase III

development for the treatment of patients in two different indications, advanced NSCLC and ovarian cancer.

BIBF 1120 is a triple angiokinase inhibitor that acts on three growth factors simultaneously: vascular endothelial

growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor

(FGFR) all crucially involved in the formation of blood vessels, which supply tumours with nutrients and oxygen

needed for the cancer to grow.

About lung cancer

Lung cancer is the world’s most common cancer and kills more people than any other cancer.In 2008, approximately 1.6

million new cases of lung cancer were diagnosed worldwide, with 1.4 million people dying from the disease.2

About breast cancer

There are more than one and a half million cases of breast cancer diagnosed each year4. It is the leading cause of

cancer deaths in women worldwide, resulting in more than 500,000 deaths per year. Breast cancer accounts for around a

third of all cancers diagnosed in women, making it the most commonly diagnosed tumour type in females5.

About head and neck cancer

Head and neck cancer can occur in over 30 different places in any of the tissues or organs in the head and neck6 and

is the sixth most frequently occurring cancer worldwide7. Most head and neck cancers are squamous cell carcinomas8

over 90% of which express EGFR9 which is critical for tumour growth.10

About ovarian cancer

Each year approximately 204,000 new cases of ovarian cancer are diagnosed in women worldwide, with an estimated

125,000 dying of the disease each year11. One of the greatest challenges in the management of ovarian cancer is that

the majority of cases are not found at an early stage11 (when definitive cure is possible by surgery) since the

tumour usually causes only non-specific symptoms, commonly attributed to non-serious causes.

Read Related Topics on Breast Cancer and Cancer Care News .

More Lung Cancer Articles

Discount Canadian Drugs

Nov 18

Breast Cancer Survival Rate – Stage 4 Breast Cancer

Posted on by


FREE Samples and Coupons for Brand Name Products!

Article by Sharon A. Jones

The breast cancer survival rate for Stage 4 breast cancer is much lower than for breast cancer detected at earlier stages.

Stage 4 breast cancer, or advanced breast cancer, has metastasized to other tissue including bone tissue, lung tissue, or the liver. When breast cancer has overwhelmed the body’s natural defenses and spread this far by the time the cancer is first diagnosed, the 5-year survival rate drops to 16%-20% in the United States (American Cancer Society).

Up to 5% of white women in the U.S., and up to 9% of black women have advanced breast cancer spread to distant tissue at the time of first diagnosis (SEER). This difference is usually attributed to poverty and lack of health insurance.

In general, women who have advanced breast cancer at the time of diagnosis live approximately 18 months after diagnosis (median survival rate). Those who are still alive five years after their diagnosis of advanced breast cancer can live an additional 3.5 years (median survival rate) according to the American Cancer Society.

Since this is the most deadly category of breast cancer, it is important to work closely with all the health care providers. New treatments are being developed all the time, and second, or even third opinions may give the patient more information about newly discovered successful solutions.

Early detection is clearly the most important factor in breast cancer survival rates. Breast cancer detected at Stage 1 while it is still localized to the breast has a survival rate of 98%-100%, while metastasized breast cancer first detected at Stage 4 drops down to 16%-20%.

Early detection procedures must include monthly self-examinations done at the same time each month. From age 20-40, healthy women should have clinical breast exams performed by their health care providers every three years. After age 40, the breast exams should be annually and should include a mammogram or similar procedure.

North American white women have the highest rates of breast cancer in the world, but the 5-year survival rate for all stages (Stage 1, Stage 2, Stage 3, and Stage 4) combined is 88% for the U.S. A recent study found European countries have lower 5-year breast cancer survival rates, with England at 77.8% and Ireland at 76.2% (Lancet Oncology).

The difference in these survival rates is usually attributed to life-saving early detection.

For more information on research showing increased breast cancer survival rates, see http://www.green-tea-health-news.com/breast-cancer-survival-rate.html

Sharon Jones has over 40 years training and experience in science, mainstream health care, and alternative health care. Her website is http://www.green-tea-health-news.com










PLEASE SUBSCRIBE! It’s Free ;-) OUR ONLINE BOUTIQUE IS NOW OPEN: www.ShopAllThingsFabulous101.com For More Fashion & Beauty Follow My Blog http My Bloglovin’ www.bloglovin.com My Chictopia www.chictopia.com My LookBook.nu www.lookbook.nu nu My Twitter www.twitter.com…
Video Rating: 4 / 5

Related Breast Cancer Articles

Discount Canadian Drugs

Nov 10

Survival and Racial Disparities Found To Be Linked Among Lung Cancer Patients

Posted on by


FREE Samples and Coupons for Brand Name Products!

Article by Katie Kelley

Copyright (c) 2009 Katie Kelley

The University of Washington-Seattle recently analyzed the results of years of lung cancer patients and found that African Americans are at an increased risk of fatalities compared to their Caucasian peers.

The study used informational data from 17,739 patients that were of the average age of 75 years old. The data was collected during the time period of 1992 to 2002. The study included patients of both races, however, 89 percent were Caucasian whereas only 6 percent were African Americans. According to the research, “black patients recommended to surgery had lung resections less frequently than white patients.”

The report found that as long as African American patients received “recommended appropriate treatment” the disparities shrank considerably, however, that has not been the case thus far, according to a Science Daily news article. Scientists were only able to speculate as to why the disparities occurred between the two races, but reasoned the following differences may be occurring:

* patients may be less inclined to undergo surgery

* patients may be have limited access to appropriate care

* patients may be less likely to visit the physician

However, if these patients had received a proper adjustment or treatment, then “no significant association between race and death” would have occurred, according to the news article.

Lung Cancer Causes

While the Oncology Channel notes that tobacco smoke is responsible for “80 percent of lung cancer deaths in men and 75 percent of lung cancer deaths in women,” there are a significant number of other risk factors that can lead to an individual’s diagnosis of lung cancer. The following are several risk factors including:

* secondhand smoke

* asbestos

* radon

* occupational exposures

* age

* race

* sex

* hereditary

It is imperative that in order for a lung cancer patient to receive the best appropriate method of treatment that he/she contact a medical professional at the first signs and symptoms of their potential condition. The Mayo Clinic reported the following as several signs and symptoms common among lung cancer patients:

* hoarseness

* wheezing

* chest pain

* coughing up blood

* development of chronic cough, also smoker’s cough

* new cough that does not go away

Defining Mesothelioma

Mesothelioma is a deadly form of lung cancer that is caused after the inhalation of asbestos fibers and dust particles has occurred. The New Zealand National Occupational Health and Safety Advisory Committee reported that individuals working in the construction industry, or a similar field, are at the most risk for developing mesothelioma cancer:

* asbestos workers

* auto mechanics

* miners

* millers

* machinery fitters

* boilermakers

* firemen

* waterside workers

* railway workers

* construction workers

Individuals who have worked in any of the above fields or a similar work environment are advised to seek medical attention if any of the above signs and symptoms develop. Additionally, it is important that an individuals suffering from mesothelioma cancer contact an environmental toxin attorney to learn about developing a mesothelioma lawsuit.

It is often necessary to create such litigation as a mesothelioma diagnosis is frequently delivered with expensive treatment options and a short life expectancy. By creating a mesothelioma lawsuit an individual is increasing their chance of receiving monetary compensation as an award for their debilitating condition.

Individuals can obtain more information on the mesothelioma risks by visiting http://mesothelioma.legalview.com or http://www.LegalView.info/. Here, readers can locate the latest on the peanut butter recall as well as how to garner legal advice from an automobile accident attorney.










Watch our video to find out more about the signs and symptoms of lung cancer, and why spotting lung cancer early is important.
Video Rating: 0 / 5


Discount Canadian Drugs

Aug 05

Breast Cancer Survival Manual, Fourth Edition: A Step-by-Step Guide for the Woman With Newly Diagnosed Breast Cancer

Posted on by

Breast Cancer Survival Manual, Fourth Edition: A Step-by-Step Guide for the Woman With Newly Diagnosed Breast Cancer

A completely updated edition of the definitive guide for patients with breast cancer
The new fourth edition of The Breast Cancer Survival Manual provides essential updates on treatment and care, enhancing the basic information that has made this the most trusted guide for women diagnosed with breast cancer for the past decade. This edition includes the most current advice on • getting a second opinion: why it’s important, what questions    to ask, and how to decide which team of doct

List Price: $ 16.00

Price: $ 8.04

Medium diamond and pink sapphire breast cancer awareness ribbon and heart in 14K

US $1,770.00
End Date: Wednesday Feb-22-2012 12:50:13 PST
Buy It Now for only: US $1,770.00
Buy it now | Add to watch list

Aug 04

Lung Cancer Survival Rate – Interpret Your Prognosis And Your Chances To Recover From Lung Cancer

Posted on by

Lung cancer survival rate comes to the portion of patients who manage to survive to the disease, for a limited period of time, after they are diagnosed as building up malignant neoplastic disease, in comparison to safe people, considering the stage and the emplacement of the cancer.
Lung cancer survival rate is built-up on the experience of important samples of patients and ordinarily concern the five years survival rate. However, we cannot anticipate what would take place to a specific patient bearing in mind the difference that exists between each case whether suffering from the disease or not.
The lung cancer survival rate depends on many factors such as the stage and the type of the disease, if there are symptoms like coughing or difficult respiration, the patient’s wellness shape and whether the malady has just been discovered or has reappeared.
There are two key types of cancer: Non small cell lung cancer very common and spreads slowly than small cell cancer.
The stage of the cancer refers to how much the illness did scatter within the lungs and the other regions of body. The data accumulated would directly influence the treatment options and monitors the progress. There are many cancer stages depending whether it concerns the small cell lung cancer or non small cell type.
Stages of the first type are: limited stage, extensive stage and recurrent. the stages interesting the other type include, occult, stages 0, 1, 2, 3 and 4 in addition to recurrent.
The symptoms can give indications about the unwellness and how it is developed. Accordingly, specialists might resolve to a specific rate.
Whether the cancer has just been diagnosed or has recurred directly determines lung cancer survival rate. In addition to the victim’s general health and her or his ability to bear one of the proposed treatment options.
Statistics do not show that the patients that survived the cancer are still under treatment or achieved remission. There are other rates, which deliver particular information like the disease-free rates, the number of survivors who accomplished remission and no longer have cancer.
The advancement free survival rate shows the amount of patients who still have the illness, however, the unwellness isn’t scattering because they got a certain success with their treatment.
Lung cancer survival rate helps, both your oncologist and you, understand your prognosis and your chances to accomplish remission by getting a more appropriate and specific treatment plan.

Get informed about this subject by visiting Lung Cancer Survival Rate

Jul 31

Survival Improved by Radiation After Breast Cancer Surgery

Posted on by

The term breast cancer refers to a malignant tumor that has developed from cells in the breast. The breast is composed of two main types of tissues: glandular tissues and stromal (supporting) tissues. Glandular tissues house the milk-producing glands (lobules) and the ducts (the milk passages) while stromal tissues include fatty and fibrous connective tissues of the breast. The breast is also made up of lymphatic tissue-immune system tissue that removes cellular fluids and waste.

There are several types of tumors that may develop within different areas of the breast. Most tumors are the result of benign (non-cancerous) changes within the breast. For example, fibrocystic change is a non-cancerous condition in which women develop cysts (accumulated packets of fluid), fibrosis (formation of scar-like connective tissue), lumpiness, areas of thickening, tenderness, or breast pain.

Mastectomy is the surgical removal of a breast. Surgery is presently the most common treatment for breast cancer. Following mastectomy, immediate or delayed breast reconstruction is possible in many instances.

There are several different types of surgical procedures used to treat breast cancer. Depending on the location or surgeon who performs the procedure, different terms may be used.

Surgical procedures for breast cancer include : -

* Simple or total mastectomy: removal of the breast, with its skin and nipple, but no lymph nodes. In some cases, a separate sentinel node biopsy is performed to remove only the first one to three axillary (armpit) lymph nodes……………..

Radiation therapy (or radiotherapy) uses high-energy rays to stop cancer cells from growing and dividing. Radiation therapy is often used to destroy any remaining breast cancer cells in the breast, chest wall, or axilla (underarm) area after surgery. Occasionally, radiation therapy is used before surgery to shrink the size of a tumor. A common treatment for early stage breast cancer is breast-conserving therapy. Breast-conserving therapy (BCT) is the surgical removal of a breast lump (lumpectomy) and a surrounding margin of normal breast tissue. BCT is typically followed by at least six to seven weeks of radiation therapy. Treatment with radiation usually begins one month after surgery, allowing the breast tissue adequate time to heal. Radiation therapy may occasionally be recommended for women to destroy remaining cancer cells after mastectomy (surgical removal of the affected breast) or to shrink tumors in patients with advanced breast cancer.

Tumors are made up of cells that are reproducing at abnormally high rates. Radiation therapy specifically acts against cells that are reproducing rapidly. Normal cells are programmed to stop reproducing (or dividing) when they come into contact with other cells. In the case of a tumor, this stop mechanism is missing, causing cells to continue to divide over and over. It is the DNA of the cell that makes it capable of reproducing.

Radiation therapy is considered to be a “local” therapy, meaning it treats a specific localized area of the body. This is in contrast to systemic therapies, such as chemotherapy, which travel throughout the body.

* external radiation therapy, where a beam of radiation is directed from outside the body, and internal radiation therapy, also called brachytherapy or implant therapy, where a source of radioactivity is surgically placed inside the body near the tumor.

* External radiation may also be called x-ray therapy, cobalt therapy, proton therapy, or intensity modulated radiation therapy (IMRT). This type of radiation is administered using a machine called a linear accelerator. Treatment can be given once or twice a day, depending on the treatment protocol being used.

Possible side effects include :-

1. Tiredness (fatigue)

2. Hair loss on the treated body part

3. Skin irritation like a bad sunburn on the treated body part

4. Nausea, vomiting or diarrhea, if the abdomen is treated

5. Mouth sores, a sore throat or dry mouth, if the head or neck is treated

These side effects usually go away within a few weeks when the treatment is finished.

There can also be long-term side effects months or years after treatment. These side effects depend on your age, how much radiation you get and what body parts are treated

1. Damage to the lungs or other organs

2. Infertility

3. Cataracts (caused by TBI)

4. Delays in growth and the ability to learn for some children

5. Risk of getting leukemia or other cancer years later (when given along with chemotherapy)

 

Please log on to :Breast Cancer

Please log on to :Radiation Therapy

We Care Core Values

“We have a very simple business model that keeps you as the center.”

Having the industry’s most elaborate and exclusive Patient Care and Clinical Coordination teams stationed at each partner hospital, we provide you the smoothest and seamless care ever imagined. With a ratio of one Patient Care Manager to five patients our patient care standards are unmatched across the sub continent.

Welcome to World Class Treatment and Surgery by We Care Health Services, India.

Contact Us : www.indiahealthtour.com

E-mail us on : info@wecareindia.com

Contact Center Tel. : (+91) 9029304141 / (+91) 022 28941902

Jul 31

Lung Cancer Survival Rates

Posted on by

Article by Blaise Farley

More people in the United States die each year due to lung disease than from breast cancer, prostate cancer and other diseases combined.

If you are one of the thousand of individuals to be diagnosed with cancer, you might have probably asked about your prognosis. You would definitely want to know if the cure for your illness is easy to come by or will become more difficult for you. Although you have the decision whether you want to learn more of it, it is still important to have an understanding of it.

Lung Cancer Survival Rates vary depending on the type of cancer diagnosed and how early it was treated.

In United States, Lung Cancer Survival Rates are fairly low. This is because of the high death rates of lung cancer that is already difficult to treat. It is ascertained through research based on the information from thousands of patients diagnosed with lung cancer.

Survival rates are measures of the percent of people that are alive after a definite point of time. It is only a statistic that indicates how long lung cancer patients can survive. The five year survival rate refers to the percentage of individuals who are alive after five years of diagnosis. The rates do not say that there is someone who is cured or if their illness has developed.

The survival rates may be alarming and confusing. The numbers may have been compiled for the statistics describing the results are from data that is several years old. Furthermore, the value do not indicate in case the survivors are still receiving treatments or if the disease is fully healed.

So, what are the uses of Lung Cancer Survival Rates? For statistical uses, these rates can help us with the information about how well we are treating the disease like lung cancer. More specific information can be acquired if you and your oncologist can talk on how it can be helpful for you.

If you have the same case with the other individuals diagnosed with similar cancer type, their medical history can offer more info about your prognosis. Another advantage of the results is that, it can suggest how patients with alike condition respond to treatments. By that then, you will be able to find out the cons and pros of each lung disease treatment option.

Lung Cancer Survival Rates are also reminders for the danger caused by smoking. Our lungs are very important, without it none of us will be able to breath. It can give an idea of how pressing the need for treatment is.

Blaise is a writer and a blogger. She is fond of researching health related information and is interested about Lung Cancer Survival Rates .










More Lung Cancer Articles